OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of canc…
$2.49+1.22%
报价 2026-11-06
市值
$81.5M
EV
$112.4M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -70.6%
$2.46$8.48
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IMDXInsight Molecular Diagnostics Inc. | $81.5M | +1.2% | -18.8% | 11.2% | – | – | – | |
| OABIOmniAb, Inc. | $733.7M | +4.1% | +58.0% | 63.6% | – | – | 312.2x | |
| CCCCC4 Therapeutics, Inc. | $381.4M | +5.1% | -25.0% | 94.9% | – | – | – | |
| PRLDPrelude Therapeutics Incorporated | $208.4M | +1.3% | +56.0% | 98.3% | – | – | – | |
| PEPGPepGen Inc. | $170.8M | +6.5% | +837.5% | 0% | – | – | – | |
| IVVDInvivyd, Inc. | $165.9M | -3.8% | +64.0% | 91.4% | – | – | – | |
| ARMPArmata Pharmaceuticals, Inc. | $130.5M | +17.0% | +13.3% | 68.2% | – | – | – | |
| CDXSCodexis, Inc. | $118.3M | +5.9% | +10.1% | 79.5% | – | – | – | |
| MISTMilestone Pharmaceuticals Inc. | $95M | +10.2% | – | 94.6% | – | – | – | |
| 同行中位数 | – | – | +56.0% | 85.4% | – | – | 312.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。